RxDoctor Payments Data

Ealeen Kim

Optometrist · Buford, GANPI 1568815322

Payments from drug & device makers

$1,653in general payments, 2019–2025

Across 65 payments — averaging $25.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$352
  • Bausch & Lomb Americas Inc.$324
  • Oyster Point Pharma, Inc.$280
  • Alcon$217
  • Tarsus Pharmaceuticals, Inc.$126
  • Harrow Eye, LLC$96
  • plus $258 from 6 others

What the payments were for

  • Food & beverage$1,63699%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,653 in reported general payments places this provider in the 65th percentile of 1,285 optometrist providers in Georgia.

See all optometrist providers in Georgia

Medicare billing

Part B allowed, 2024
$152,634
Medicare patients
809
Services billed
1,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine61$85,589
XiidraLifitegrast23$47,364
LumiganBimatoprost87$40,513
Cyclosporine37$31,959
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol24$7,645
SimbrinzaBrinzolamide/Brimonidine Tart26$7,187
Latanoprost263$3,684
Prednisolone Acetate88$3,323
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat105$1,920
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha67$666
Timolol Maleate46$346
Ketorolac Tromethamine15$336
Dorzolamide Hcl13$174
Brimonidine Tartrate13$115
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav18$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$34$126,103148 claims
Bausch & Lomb Americas Inc.Xiidra$324$47,36423 claims
AlconSimbrinza$217$7,18726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,285 optometrist providers in Georgia.

Other optometrist in Buford

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →